Vivos Therapeutics, Inc. 8-K — AI Bull & Bear Analysis

Vivos Therapeutics finds itself at a critical crossroads, balancing a desperate need for capital against the threat of losing its Nasdaq listing. The filing reveals a company attempting to trade equity for survival, utilizing a combination of debt-to-equity swaps and new convertible notes to bridge a widening funding gap. While these moves provide a temporary reprieve, the company's ability to survive depends entirely on its capacity to raise additional millions in equity by the end of 2026.